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Summary Keratoacanthomas (KAs) resemble squamous cell carcinomas (SCCs) except that, unlike SCCs,
after a period ofrapid growth over a few months they involute completely. The basis of their regressing natural
history is not known. We have examined keratoacanthomas and another benign cutaneous tumour, the basal
cell papilloma (BCP), for loss ofheterozygosity (LOH) at a number of loci that are frequently lost in SCCs and
other skin tumours. The frequency of LOH for both KAs and BCPs was low, with only isolated losses
identified at 9p, 9q and 10q in KAs [fractional allelic loss (FAL) was 1.3%], and at 9p and 17p in BCPs (FAL
was 0.4%). This contrasts with previous work showing a FAL of 32% in SCC and 46% in actinic keratoses.
The results show a clear difference between KA and SCC and do not support the hypothesis that KAs are
SCCs that regress as a result ofexternal (host) influences but rather suggest that KAs and SCCs are different de
novo. LOH around the locus implicated in the multiple self-healing epitheliomata of Ferguson-Smith (9q22-
q31) was shown in only 1 of 11 KAs.
Keywords: keratoacanthoma; benign cell papilloma; loss of heterozygosity; multiple self-healing squamous
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Current cellular theories of carcinogenesis emphasise the
multistage nature of cancer in which there is thought to be a
causal relation between the accumulation of genetic
abnormalities and the clinical and biological behaviour of
the tumour (Weinberg, 1991; Fearon and Vogelstein, 1990;
Yokota and Sugimura, 1993). In humans the clearest example
is probably the development of colorectal carcinoma, and in
the mouse the development of cutaneous squamous cell
carcinoma (SCC) and spindle cell carcinoma following topical
application of chemical carcinogens (for reviews see Fearon
and Vogelstein, 1990; Burns et al., 1991). Non-melanoma
skin cancer (NMSC), the commonest human malignancy in
many Caucasian populations (Weinstock, 1994), offers a
number of opportunities for the investigation of the
relationship between genetic change and tumour phenotype.
The occurrence of a range of different tumour types, all
keratinocyte derived and related to ultraviolet radiation
(UVR), with markedly different clinical behaviours, and in
particular the presence of a number of neoplastic lesions,
such as keratoacanthomas (KAs), that show spontaneous
regression are of considerable experimental interest (Rees,
1994). KAs are a common keratinising squamous neoplasm,
classically occurring on the JVR-exposed skin of elderly
individuals, which are characterised clinically by a period of
rapid growth over a 4-12 week period followed by
spontaneous involution (Schwartz, 1994; Straka and Grant-
Kels, 1991; Ghadially and Ghadially, 1993). Histologically
KAs resemble SCCs, and although on occasions the
histological differentiation from SCC may be difficult their
biologically benign course allows clear differentiation (Straka
and Grant-Kels, 1991; Schwartz, 1994). A number of
pathogenic abnormalities have been described in KAs,
including H-ras mutations, aneuploidy, altered p53 immu-
nostaining and the presence of human papillomavirus (HPV)
DNA (Corominas et al., 1989; Newton et al., 1987; Herzberg
et al., 1991; Kerschmann et al., 1994; Stephenson et al., 1992;
Lee and Teh, 1994; Schwartz, 1994).
The genetic changes underlying KA are of interest for a
number of reasons. Firstly, putative causal changes appear to
be insufficient to allow the tumour to maintain its integrity
and prolonged growth in the host; comparisons with the
genetic changes found in SCC may therefore be interesting
(Quinn et al., 1994b). Secondly, a related tumour, the familial
multiple self-healing squamous epithelioma (MSSE) of
Ferguson-Smith, maps to chromosome 9q22-q31 (Goudie
et al., 1993). Although there may be histological differences
between sporadic KA and MSSE, many consider the MSSE a
form offamilial KA (Straka and Grant-Kels, 1991; Schwartz,
1994); reports of multiple KAs occurring sporadically also
suggest overlap (Witten and Zak, 1952). A final reason for
interest in the genetics of KAs is the finding that another
cutaneous lesion, actinic keratoses (AK) (small scaly red
lesions occurring on UVR-exposed skin showing varying
degrees of dysplasia), which also show a high rate of
spontaneous regression (Marks et al., 1986), show a
frequency of allelic loss similar to, if not higher than, SCC
(Rehman et al., 1994). One of a number of interpretations of
the allelotype data of AK is that accumulation of genetic
change in skin tumours may be associated with both
progression and regression (Rees, 1994; Rehman et al.,
1994). KAs provide a natural group of lesions on which to
examine further the relation between genetic change and
clinical behaviour, and we have therefore carried out loss of
heterozygosity (LOH) analysis at a number of loci implicated
in SCC development in a series of KAs. In order to aid
interpretation and as further controls, we have carried out a
similar analysis on basal cell papillomas (BCP) ('seborrhoeic
keratosis'), benign lesions that are histologically characterised
by thickening of the epidermis with keratinocyte immaturity,
but with no known relation to either basal cell carcinoma
(BCC) or SCC or any dysplasia of the skin (Mackie, 1992).
Materials and methods
Clinical samples
Twenty-four archival blocks with a diagnosis of sporadic KA
and 27 blocks with a diagnosis of basal cell papilloma were
retrieved for analysis from the Royal Victoria Infirmary,
Newcastle upon Tyne. Clinical records and histology were
reassessed by an independent clinician and dermatopatholo-
gist, with the histology being assessed without knowledge of
the clinical course. Only samples that showed the typical
histology of proliferating, fully developed or involutionary
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stages of keratoacanthoma and a clinical history of rapid
growth (lesions less than 3 months old) are referred to as
'definite KAs' (Straka and Grant-Kels, 1991; Schwartz,
1994). Paraffin-embedded sections (20 ,um) of tumour
material (dewaxed) were microdissected from surrounding
inflammatory infiltrate and normal skin on an inverted
microscope. Tumour DNA and DNA from normal adjacent
skin was isolated according to standard methods by
proteinase K digestion and phenol-chloroform extraction
(Jackson et al., 1992).
Analysis of loss of heterozygosity
PCR amplification of microsatellite polymorphisms was
carried out with approximately 100 ng of template DNA
with 200 mM deoxynucleotide triphosphates, 1 pmol of each
oligonucleotide primer (Research Genetics, Huntsville, USA),
one of which was end-labelled with 32P-ATP, and 1 U of Taq
DNA polymerase (Biotaq; Bioline, London, UK) in 20 dl.
Amplification consisted of 30 cycles of 1 min at 95°C, 1 min
at 55'C and 1 min at 72°C with a final 10 min extension time
of 72°C. Loading buffer (10 ,l) was added at the end of each
reaction and samples were heat denatured and electrophor-
esed through 6% denaturing polyacrylamide gels. Gels were
fixed in 10% acetic acid- 10% methanol, vacuum dried and
exposed to Fuji XR film for up to 24 h. Allelic loss was
scored without knowledge of the putative tumour type and
independently of the re-reviewed histological and clinical
details. A significant reduction in the signal intensity of one
of the two tumour alleles was recorded as LOH (although
this does not formally exclude allelic imbalance secondary to
amplification of one allele).
LOH analysis was carried out for loci that previous studies
have shown to be frequently lost in SCC and AK (3p, 9p,
13q, 17p and 17q) (Quinn et al., 1994b; Rehman et al., 1994),
and on other arms chosen at random (see Table I). Loci of
markers are referred to as described by Weissenbach et al.
(1992). The frequency of LOH at a locus is given by the
number of losses at the locus divided by the number of
tumours informative for that locus. The fractional allelic loss
Table I Frequency of loss ofmicrosatellite markers used for LOH
analysis of 11 keratoacanthomas (KAs) and 27 basal cell papillomas
(BCPs); numbers of tumours showing loss/number of informative
cases at each chromosome arm. Markers are described by
Weissenbach et al. (1992)
Definite Probable
Chromosome Locus KAs KAs BCPs
lp DIS201 0/8 0/9 0/16
lq DIS212 0/10 0/11 0/17
2p D2S149 0/7 0/10 0/24
2q D2S163 0/10 0/10 0/21
3p D3S1293 0/9 2/11 0/23
3q D3S1268 0/9 0/7 0/22
4p D4S394 0/9 0/8 0/12
4q D4S402 0/8 0/8 0/19
5p D5S419 0/10 0/9 0/19
5q D5S410 0/8 0/6 0/22
6p D6S299 0/8 0/9 0/23
6q D6S262 0/8 0/11 0/23
7p D7S481 0/8 0/7 0/9
9p D9S171 1/7 1/8 0/19
9q D9S160 1/9 0/9 1/16
10q DIOS185 1/7 0/7 ND
1lp DIIS922 0/11 0/10 0/27
llq DIIS910 0/5 0/7 ND
12q D12S86 0/11 0/9 0/25
13q D13S170 0/9 0/10 0/14
17p D17S796 0/10 1/7 1/19
17q D17S785 0/8 1/7 0/19
18p D18S59 0/11 0/8 0/21
18q D18S70 0/9 0/10 0/21
21q D21S262 0/8 0/4 ND
22q D22S283 0/11 0/9 0/22
ND, no data.
(FAL) is given by summing the LOH score at all loci and
dividing by the number of tumours examined that were
informative at the loci. In view of the mapping of two
familial skin cancer syndromes [naevoid basal cell carcinoma
syndrome (NBCCS) and MSSE] to 9q22-q31 (Farndon et
al., 1992; Gailani et al., 1992; Goudie et al., 1993), and
evidence from LOH studies of a putative tumour-suppressor
gene on 9p for cutaneous SCC (Quinn et al., 1994a, b, c), a
more detailed analysis using multiple markers on chromo-
some 9 was carried out on the keratoacanthomas.
Results
Tumour sample diagnosis
Review of the histology and clinical details confirmed the
original diagnosis in all the basal cell papillomas. However
adoption of strict criteria relying on both characteristic
clinical history and histopathological assessment for the
diagnosis of KA showed that in only 11 of the 24 putative
tumours could a definite diagnosis of KA be sustained for the
purposes of this study (referred to as 'definite KAs'). Of the
remaining samples, one block contained only normal tissue,
another was clearly a SCC, and the histology or the clinical
history in the other cases was not classical, although the
likely diagnosis was thought to be KA. Where tissue was
available, and with the exception of the definite SCC, these
samples were analysed and are referred to as 'probable KAs'
(n = 11).
LOH in keratoacanthomas and basal cell papillomas
The frequency of LOH for both KAs and benign papillomas
was low with only isolated losses identified (Table I). Of the
11 'definite KAs' only two tumours showed LOH occurring
at a total of three loci; one KA showed allelic loss on
chromosome arms 9p (D9S162) and 10q (D1OS185), one
showed allelic loss on chromosome arm 9q (D9S160) (Figure
1), and the other nine KAs showed no LOH at any of the
chromosome arms analysed. The FAL based on the 26 loci
examined was 1.3% (3/228). Of the 27 BCPs studied LOH
was identified in only two tumours; one showed LOH at 9q
(D9S160) and the other at 17p (D17S796) (Figure 2). The
FAL based on the 23 loci examined was 0.4% (2/453).
Analysis of the 'probable KAs' (those that did not meet
strict histological and clinical criteria) was also carried out.
These 11 lesions showed a low frequency of loss with a FAL
score based on the 26 loci examined of 2.2% (5/222) with
LOH occurring at 3p (2/11), 9p (1/8), 17p (1/7) and 17q (1/7).
By contrast, the one lesion recognised as a SCC showed LOH
at 7 of 20 informative chromosome markers (3p, 3q, 9p, 9q,
1Oq, 17p and 18p).
Deletion mapping of chromosome 9 in the definite
keratoacanthomas
The pattern of chromosome 9 loss was examined in more
detail in all 11 definite KAs using ten microsatellite markers.
One KA showed loss of distal 9p markers D9S162 and
D9S171 with retention of 9p markers centromeric to D9S171
and all informative 9q markers examined (D9S169, D9S166,
D9S167, D9S152, D9S176 and D9S160). The area of loss in
this lesion encompassed the interferon cluster at 9p21-q22
and the region containing the genes coding for p16 and p15
(Olopade et al., 1992; Kamb et al., 1994; Nobori et al., 1994;
Weaver-Feldhaus et al., 1994). One other KA showed loss of
9q markers D9S160 and D9S176. However, attempts to
further define the extent of loss of chromosome 9 in this
lesion were impossible because analysis with other proximal
9q markers and 9p markers (D9S180, D9S152, D9S167 and
D9S166, D9S165, D9S169, D9S171 and D9S162) was either
uninformative or gave no PCR product. The area of loss in
this tumour encompassed the locus or loci underlying the
NBCCS and the MSSE syndrome at 9q22-q31 (Gailani et
al., 1992; Farndon et al., 1992; Goudie et al., 1993).LOH analysis of keratoacanthoma
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There are many similarities between KAs and SCCs; for any
one tumour, no single investigation can distinguish them
reliably (Straka and Grant-Kels, 1991; Mackie, 1992;
Schwartz, 1994). Both types of lesions may share a similar
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Figure 1 (a) Representative autoradiograph showing allele loss
in keratoacanthoma and squamous cell carcinoma at D9S162
(chromosome arm 9p). Lanes 1-8 show PCR product from
normal (N) and tumour (T) DNA from four patients with KAs.
Lanes 9-10 show PCR product from normal and tumour DNA
from one patient with SCC. One KA in lane 6 and the SCC in
lane 10 show a diminished or absent band indicating LOH at
D9S162. (b) Representative autoradiograph showing allele loss in
keratoacanthoma at DIOS185 (chromosome arm 10q). Lanes 1-6
show PCR product from normal and tumour DNA from three
patients with KAs. One KA in lane 4 shows LOH at D10S185.
Figure 2 Representative autoradiograph showing allele loss in
basal cell papillomas at D9S160 (chromosome arm 9q). Lanes 1-
9 show PCR product from normal (N) and tumour (T) DNA
from four patients with BCPs. Lanes 8 and 9 show analysis of
tumour DNA from one patient with two BCPs; one of these
BCPs in lane 9 shows LOH at D9S160.
clinical and histopathological appearance; both occur
predominantly on sun-exposed skin and are more common
in patients receiving immunosuppressive therapy; both KAs
and SCCs can be induced by the same chemical carcinogen
protocols in animals; and both have been reported to be
associated with HPV infection (although whether this plays a
causal role is unknown) (Gassenmaier et al., 1986; Pfister et
al., 1986; Kwa et al., 1992; Schwartz, 1994). Studies assessing
DNA ploidy levels, nuclear morphometry, p53 immunostain-
ing, nm23 expression and a variety of morphological criteria
have all shown overlap between KAs and SCCs (Herzberg et
al., 1991; Miracco et al., 1992; Seidman et al., 1992;
Stephenson et al., 1992, 1993; Helander et al., 1993). The
only consistent difference lies in the characteristic clinical
natural history of rapid growth followed by spontaneous
involution of the KA compared with the persistence and
possible metastasis of the SCC (Kwa et al., 1992).
A number of arguments have been advanced to explain the
natural history of KAs, including that they are follicular
tumours with the period of growth and involution reflecting
the normal hair cycle periods of anagen and catagen; that
involution is immunologically mediated; and that KAs are
associated with genetic events (including ras mutations) that
lead to regression rather than progression (Ramselaar and
van der Meer, 1976, 1979; Ramselaar et al., 1980; Corominas
et al., 1989; Straka and Grant-Kels, 1991; Patel et al., 1994;
Schwartz, 1994). There is support for and against each of
these hypotheses and none of these explanations of KA
involution is mutually exclusive.
The majority of KAs in the present study showed no LOH
at any of the markers studied whereas LOH is common on
chromosome arms 3p, 9p, 9q, 13q, 17p and 17q in SCCs and
AKs. The FAL score for the KAs ('definite KAs') at these six
loci of4% (2/50) contrasts with the corresponding FAL score
of 32% for the SCCs and 46% for the AKs (Quinn et al.,
1994b; Rehman et al., 1994). The results are also different
from the 59% LOH seen on 9q for basal cell carcinomas
(Quinn et al., 1994b). The inclusion of only lesions that had
both typical histological features and a characteristic clinical
history in the KA group make it unlikely that the results are
due to misdiagnosis of KAs as SCCs. The fact that a similar
FAL score was seen in the 'probable KA' group is reassuring
in this respect. Our previous findings showing a high
frequency of LOH on chromosome 9 in basal cell
DiscussionLOH analysis of keratoacanthoma
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carcinomas (Quinn et al., 1994b), and a high FAL in AKs
which are much smaller lesions than KAs (Rehman et al.,
1994), also argues against technical failure owing to an
inability to separate tumour from stroma.
The rarity of LOH in KAs has bearings on their
pathogenesis. Firstly it suggests that attempts to explain the
involution of KAs on the basis that they are really SCCs that
are for some other reason subsequently attacked by the
immune system may be mistaken (Patel et al., 1994).
Secondly the failure to find LOH around the locus
responsible for the MSSE syndrome is worthy of comment.
There are differences of opinion about the nature of the
tumours seen in MSSE with many authors referring to them
as KAs, whereas others argue that they are a specific form of
SCC that undergoes involution (Straka and Grant-Kels,
1991; Mackie, 1992; Ghadially and Ghadially, 1993;
Schwartz, 1994). The finding of LOH in only 1 of 11
sporadic KAs at loci close to the MSSE/naevoid basal cell
carcinoma syndrome at 9q22-q31 raises the possibility that
the tumours are not equivalent genetically. However, in the
absence of studies showing LOH in MSSE lesions, the
comparison may not be valid as not all familial cancer
susceptibility genes are accompanied by LOH: we cannot
therefore exclude the same gene's involvement in sporadic
KA and MSSE. The infrequent LOH on chromosome 9 is
also of interest in the light of theories suggesting that KAs
are follicular (or more strictly appendageal) in origin. Several
lines ofevidence suggest that BCC are derived from follicular
cell progenitors (Miller, 199la, b), and hence the absence of
LOH on chromosome 9 argues that if KA are follicular then
they have a different pathogenesis from BCC.
LOH on chromosome 17 was seldom seen in the KAs,
whereas loss involving a number of markers on chromosome
17 is commonly seen in other forms of NMSC including
AKs, Bowen's disease and SCC (Rehman et al., 1994; Ziegler
et al., 1994), as is the presence of p53 mutation (Campbell et
al., 1993b; Brash et al., 1991; Ziegler et al., 1994). This
suggests a further difference between KA and SCCs, although
it is not possible to exclude a role for p53 in KA as other
methods of inactivating p53 may occur in KA; for instance
mutations on both alleles ofp53 as has been reported in BCC
(Campbell et al., 1993a; Ziegler et al., 1993), small deletions,
or interaction with proteins that may target p53 degradation
or interfere in the p53 pathway all of which could have been
missed. Other studies have however failed to find p53
mutations in KAs (Kubo et al., 1994).
The finding of occasional LOH in the BCPs and two of
the KAs is open to a number of interpretations besides the
obvious one that these changes are causally related to the
pathogenesis of these lesions. Evidence of LOH does however
suggest that these lesions are clonal. The fact that the two
KAs showing LOH showed LOH on chromosome 9, and the
involvement of loci on chromosome 9 in other forms of skin
cancer, might be interpreted as support for these abnormal-
ities being causally important in KA pathogenesis. Similarly
in the 'probable KA' group LOH occurred at loci known to
be lost at high frequency in SCC and AK, namely
chromosome arms 3p, 9p, 17p and 17q. However,
inevitably, interpretation of the probable KA results is
difficult, as although most of the lesions are likely to
represent KA, squamous cell carcinoma in one or more of
the samples cannot be excluded, and the presence of SCC
would clearly bias the results towards loss of those areas that
occur in SCC development. An alternative, and perhaps less
likely, hypothesis is that the LOH may be unrelated to the
development of the lesion but merely reflects background
LOH in the proliferative compartment in skin.
In summary the LOH data show a clear difference between
KAs and SCCs. The interpretation of KAs as de novo
squamous cell carcinomas which for some other reason
involute seems unlikely, rather the results suggest that from
early in their pathogenesis KAs are distinct from SCC. The
low level of LOH in KAs contrasts with the predominantly
isolated loss on chromosome 9 that occurs in basal cell
carcinoma and the high frequency of LOH in lesions such as
actinic keratoses that are also keratinocyte-derived and show
a high rate of regression.
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